Literature DB >> 19745756

Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA.

Myron J Tong1, Disaya Chavalitdhamrong, David S K Lu, Steven S Raman, Antoinette Gomes, John P Duffy, Johnny C Hong, Ronald W Busuttil.   

Abstract

BACKGROUND/RATIONALE: Hepatocellular carcinoma (HCC) is a common malignancy in Asians and is related to the high incidence of chronic viral hepatitis in this ethnic population. The aims of this study were to examine the tumor characteristics and liver disease status in HCC patients of Asian ancestry and determine their survival after treatments for HCC.
RESULTS: Between September 2000 and December 2007, 278 patients, mean age 61.5 years, presented with HCC to the University of California Los Angeles (UCLA) Liver Cancer Center. Hepatitis B (HBV) infection was detected in up to 68% of Chinese, Korean, and Vietnamese patients, whereas 60% of Japanese patients had Hepatitis C (HCV) infection. Compared with HCC patients who presented with symptoms, those detected by surveillance had more tumors within the Milan and University of California, San Francisco (UCSF) criteria and more patients in Child-Turcotte-Pugh class A. On the basis of a predefined UCLA treatment algorithm, 83% of patients received surgical and/or loco-regional therapies. Compared with other treatments, orthotopic liver transplantation (OLT), and radiofrequency ablation had the highest overall patient survival (P<0.0001) and OLT has the highest disease free survival rates (P<0.0001). Independent baseline predictors for: (1) patient survival were HBV [hazard ratio (HR) 0.62, P=0.005], UCSF criteria (HR 0.46, P<0.0001), Child Turcotte Pugh class A (HR 0.57, P=0.005), alphafetoprotein per log10 increase (HR 1.26, P=0.0012), and alkaline phosphatase per log10 increase (HR 2.32, P=0.02); and for (2) disease free survival were UCSF criteria (HR 0.66 P=0.007), aspartate aminotransferase per log10 increase (HR 1.50, P=0.04), and age per year increase (HR=1.02, P=0.04). The 4 Asian subgroups had similar survival rates.
CONCLUSIONS: HBV and Hepatitis C were associated with over 90% of HCC cases in Asian Americans. HCC detected by surveillance identified more patients eligible for surgical and loco-regional therapies, which improved the overall and disease free survival.

Entities:  

Mesh:

Year:  2010        PMID: 19745756     DOI: 10.1097/MCG.0b013e3181b4b68b

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  15 in total

1.  Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study.

Authors:  Mohamed Abd El-Fattah; Mohamed Aboelmagd; Mohammed Elhamouly
Journal:  United European Gastroenterol J       Date:  2016-07-09       Impact factor: 4.623

Review 2.  Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States.

Authors:  D Tan; A Yopp; M S Beg; P Gopal; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

3.  Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence?

Authors:  Ming-Chin Yu; Kun-Ming Chan; Chen-Fang Lee; Yun-Shien Lee; Firas Zahr Eldeen; Hong-Shiue Chou; Wei-Chen Lee; Miin-Fu Chen
Journal:  J Gastrointest Surg       Date:  2011-05-04       Impact factor: 3.452

4.  Disparities in hepatocellular carcinoma survival among Californians of Asian ancestry, 1988 to 2007.

Authors:  Sandy L Kwong; Susan L Stewart; Christopher A Aoki; Moon S Chen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-07       Impact factor: 4.254

5.  Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians.

Authors:  Ellen T Chang; Juan Yang; Theresa Alfaro-Velcamp; Samuel K S So; Sally L Glaser; Scarlett Lin Gomez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-12       Impact factor: 4.254

6.  Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma.

Authors:  Benjamin Yip; James M Wantuck; Lily H Kim; Robert J Wong; Aijaz Ahmed; Gabriel Garcia; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

7.  Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic.

Authors:  Myron J Tong; Hai-En Sun; Carlos Hsien; David S K Lu
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

8.  Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma.

Authors:  Jong Man Kim; Choon Hyuck; David Kwon; Jae-Won Joh; Joon Hyeok Lee; Seung Woon Paik; Cheol Keun Park
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

9.  Both HCV and HBV are major causes of liver cancer in Southeast Asians.

Authors:  Hillary Lin; Nghiem B Ha; Aijaz Ahmed; Walid Ayoub; Tami J Daugherty; Glen A Lutchman; Gabriel Garcia; Mindie H Nguyen
Journal:  J Immigr Minor Health       Date:  2013-12

10.  Striking Racial/Ethnic Disparities in Liver Cancer Incidence Rates and Temporal Trends in California, 1988-2012.

Authors:  Christopher Pham; Tse-Ling Fong; Juanjuan Zhang; Lihua Liu
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.